Oncology company Novocure (NASDAQ: NVCR) announced on Wednesday the success of its phase 3 METIS clinical trial, revealing a significant improvement in time to intracranial progression for non-small cell lung cancer (NSCLC) patients treated with Tumor Treating Fields (TTFields) therapy alongside supportive care.
Patients experienced a median time to intracranial progression of 21.9 months, compared to 11.3 months for those receiving supportive care alone. The treatment was well-tolerated with sustained quality of life and neurocognitive function.
METIS, involving 298 patients, demonstrated the efficacy of TTFields therapy in treating 1-10 brain metastases from NSCLC post-stereotactic radiosurgery.
Novocure intends to submit the data to regulatory authorities and publish findings in a peer-reviewed journal.
Brain metastases are common in NSCLC patients, affecting quality of life and prognosis. TTFields therapy offers a promising treatment option with minimal neurocognitive adverse events.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member